Passage Bio, Inc. (PASG) - מכפיל P/S עתידי

Insurance fund reimbursement for rare brain pathology therapies creates the financial foundation for Passage Bio, Inc. (PASG). The projected P/S multiple reflects market expectations, where the mark characterizes this parameter. Passage Bio, Inc. (PASG) relies on AAV-vector gene delivery to treat orphan diseases, yet intense investor pressure is forcing the company to accelerate trials in competition with global players.

To protect capital from volatility, it is crucial for investors to understand the extent to which the market capitalization of Passage Bio, Inc. (PASG) is justified by future sales expectations. The global expansion of CNS gene therapy via AAV vectors drives the projected P/S trend, which measures the market's willingness to pay a premium for future revenue; a sharp rise in the line signals optimism regarding the commercial capture of the neuropharma sector, but warns of the risk of overvalued assets.